SOPHiA GENETICS (SOPH) CSO Xu Zhenyu Exercises Options, Sells Shares

What Happened
Xu Zhenyu, Chief Scientific Officer of SOPHiA GENETICS (SOPH), exercised a total of 10,000 stock options (3,000 on 2026-08-05 and 7,000 on 2026-08-07) at an exercise price of $3.28 per share (total cost $32,800). He sold a total of 20,000 shares in open-market transactions (3,000 on 8/05 at a weighted $7.00, 7,000 on 8/07 at a weighted $7.02, and 10,000 on 8/07 at a weighted $7.48), generating about $144,924 in proceeds. The exercised shares were effectively converted and sold (cashless-style), and additional already-held shares were also sold. Overall this involved an exercise (M) and multiple sales (S).

Key Details

• Transaction dates: 2026-08-05 and 2026-08-07 (Form 4 filed 2026-08-07). Filing appears timely.
• Options exercised: 10,000 shares at $3.28 each (total cost $32,800). Options are reported as fully vested.
• Shares sold: 20,000 shares for total proceeds ≈ $144,924 (broken out as 3,000 @ $7.00; 7,000 @ $7.02; 10,000 @ $7.48).
• Net proceeds vs. exercise cost: roughly $144,924 proceeds less $32,800 exercise cost = ≈ $112,124 realized difference.
• Holdings after transactions: reporting shows remaining derivative share options of 982,041 after one line and 975,041 after the later line (reflecting the successive exercises).
• Notable footnotes: sales were made pursuant to a Rule 10b5-1 trading plan (F1). Reported sale prices are weighted averages across multiple trades with ranges $7.00–$7.08 and $7.40–$7.56 (F2, F3); full per-trade breakdown available on request. Options are fully vested (F4).
• Transaction codes: M = option exercise/conversion, S = open-market sale.

Context and implications

• This was an exercise of vested options followed by sales (a common way insiders realize gains). The combination of exercising and immediately selling indicates a cash-proceeds/monetization event rather than a new long-term purchase.
• The presence of a 10b5-1 plan means the sales were made under a pre-arranged trading program, which is intended to reduce concerns about trading on non-public information.
• These filings are factual disclosures of insider activity; they do not by themselves indicate company performance or management sentiment beyond the reported transactions.